secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADC Therapeutics SA (ADCT)
CIK:        0001771910
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001628280-24-045995
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ADC Therapeutics reports Q3 2024 revenue $18.0M; net loss narrows; discontinues ADCT-601
--------------------------------------------------------------------------------

- ZYNLONTA net product revenue $18.0M in Q3 2024 vs $14.3M in Q3 2023; year-to-date $52.9M.
- Net loss $44.0M ($0.42 per share) in Q3 2024 vs $46.7M ($0.57) in Q3 2023; adjusted net loss $29.4M.
- Cash and cash equivalents $274.3M as of Sep 30, 2024; expected runway into mid-2026.
- Discontinued ADCT-601 (AXL-targeting) due to unfavorable benefit-risk; prioritizing exatecan-based ADC platform.
- LOTIS-5 Phase 3 trial (ZYNLONTA+rituximab) full enrollment expected by year-end 2024; LOTIS-7 data update in Dec 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1771910/000162828024045995/0001628280-24-045995-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1771910/000162828024045995/adc-20241107.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-045995

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer